专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5597578A TGF-.beta. protein compositions for inhibition of cell proliferation 失效
标题翻译：用于抑制细胞增殖的TGF-β蛋白组合物
公开(公告)号：US5597578A
公开(公告)日：1997-01-28
申请号：US234509
申请日：1994-04-28
申请人： Dennis M. Brown , Edward Luck , Daniel R. Twardzik , Anthony F. Purchio
发明人： Dennis M. Brown , Edward Luck , Daniel R. Twardzik , Anthony F. Purchio
IPC分类号： A61K31/135 , A61K9/00 , A61K38/00 , A61K38/17 , A61K38/18 , A61K47/42 , A61K47/48 , A61P35/00 , C07K14/00 , C07K14/435 , C07K14/495 , C07K14/52 , C07K17/04 , A61K9/10 , A61K38/39
CPC分类号： A61K9/0024 , A61K38/1841 , A61K47/42 , A61K47/48269
摘要： Antiproliferative compositions are provided which are capable of sustained release of an antiproliferative agent, particularly a TGF-.beta., at a site proximal to a target cell. The compositions are effective in inhibiting proliferation of the target cell, particularly when used in combination with a vasoconstrictive agent.
摘要翻译：提供抗增殖组合物，其能够在靶细胞附近的部位持续释放抗增殖剂，特别是TGF-β。所述组合物有效抑制靶细胞的增殖，特别是当与血管收缩剂组合使用时。

2. 发明授权

US10383847B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo 有权
公开(公告)号：US10383847B2
公开(公告)日：2019-08-20
申请号：US14250958
申请日：2014-04-11
申请人： Dennis M. Brown , Ian Nisbet
发明人： Dennis M. Brown , Ian Nisbet
IPC分类号： A61K31/404 , A61K45/06 , C07K16/40 , C12N15/113 , A61K31/7056 , A61K39/395 , C07D209/34
摘要： The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo. In particular, the therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo, are effective Nek9 inhibitors. The active agent, such as meisoindigo, can act as a Nek9 inhibitor. The active agent can be used together with Nek9 inhibitors or agents that inhibit the expression of Nek9.

3. 发明申请

US20190175541A1 USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES 审中-公开
公开(公告)号：US20190175541A1
公开(公告)日：2019-06-13
申请号：US15771631
申请日：2016-10-26
申请人： Jeffrey A. BACHA , Dennis M. BROWN , Anne STEINØ , DelMar Pharmaceuticals, Inc.
发明人： Jeffrey A. Bacha , Dennis M. Brown , Anne Steinø
IPC分类号： A61K31/336 , A61P35/00 , A61K31/282 , A61K31/4745 , A61K31/502 , A61K31/7048 , A61K33/24 , A61N5/10
摘要： The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.

4. 发明授权

US10138264B2 Recombined molecules and preparation thereof 有权
公开(公告)号：US10138264B2
公开(公告)日：2018-11-27
申请号：US13039055
申请日：2011-03-02
申请人： Dennis M. Brown
发明人： Dennis M. Brown
IPC分类号： C12P17/18 , C12P19/26 , C40B50/00 , C07H17/08 , C07H21/04 , C07K1/04 , C07K1/107 , C07K9/00 , C12P1/00 , C12P7/44 , C12P7/46 , C12P13/04 , C12P17/04 , C12P19/00
摘要： The invention relates to novel molecules and libraries thereof as well as methods for their production. Methods of producing the novel molecules include the cleaving of starting molecules into molecular subunits and the assembly of the subunits into novel recombined molecules.

5. 发明申请

US20120207855A1 CEPHALOTAXINE ALKALOID COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译： CEPHALOTAXINE ALKALOID组合物及其用途
公开(公告)号：US20120207855A1
公开(公告)日：2012-08-16
申请号：US13336917
申请日：2011-12-23
申请人： Dennis M. Brown
发明人： Dennis M. Brown
IPC分类号： A61K33/24 , A61P35/00 , A61K31/55
CPC分类号： A61K45/06 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/55 , A61K31/70 , A61K31/7048 , A61K31/7076 , A61K33/24 , A61K2300/00
摘要： A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.
摘要翻译：描述了一种治疗具有细胞增殖性疾病的宿主的方法，包括使宿主与足以调节所述细胞增殖性疾病的量的头孢噻肟和抗增殖剂接触。在一些实施方案中，头孢噻肟含有高粱素（头孢噻肟，4-甲基-2-羟基-2-（4-羟基-4-甲基戊基）丁二酸酯）。本发明的抗增殖剂包括烷化剂，嵌入剂，金属配位络合物，嘧啶核苷，嘌呤核苷，核酸相关酶和蛋白质的抑制剂以及影响结构蛋白和细胞质酶的试剂。

6. 发明申请

US20120058991A1 Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine 审中-公开
标题翻译：头孢噻肟的配方和方法，包括Homoharringtonine
公开(公告)号：US20120058991A1
公开(公告)日：2012-03-08
申请号：US13294776
申请日：2011-11-11
申请人： Dennis M. Brown
发明人： Dennis M. Brown
IPC分类号： A61K31/55 , A61P35/00 , A61P35/02 , C07D491/147
CPC分类号： A61K36/13 , A61K31/55 , C07D419/14 , C07D491/20
摘要： The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.
摘要翻译：本发明涉及用于治疗患有头孢噻肟的患者的组合物和方法，例如高质蛋白胨。本发明还涉及改善用于治疗癌症和其它异常细胞疾病的同型异亮氨酸的纯度，制造方法，制剂和给药。本发明还提供了抗寄生虫，抗真菌，抗病毒和抗菌处理的方法和组合物。

7. 发明授权

US5874402A Use of cell membrane permeants in the treatment of cellular proliferative diseases 失效
标题翻译：细胞膜渗透剂在细胞增殖性疾病的治疗中的应用
公开(公告)号：US5874402A
公开(公告)日：1999-02-23
申请号：US857736
申请日：1997-05-16
申请人： Saira Singh , Richard E. Jones , Dennis M. Brown
发明人： Saira Singh , Richard E. Jones , Dennis M. Brown
IPC分类号： A61K47/00 , A61K31/00 , A61K31/475 , A61K38/00 , A61K38/19 , A61K47/26 , A61K47/28 , A61K47/42 , A61K47/46 , A61P35/00 , A61K31/435
CPC分类号： A61K47/46 , A61K31/475 , A61K38/191 , Y10S514/801 , Y10S514/802 , Y10S514/946 , Y10S514/947
摘要： Methods are provided for the treatment of a host suffering from a cellular proliferative disease through administration of a chemotherapeutic agent in conjunction with a cell membrane permeant. Optionally, the cell membrane permeant and/or chemotherapeutic agent will be present in a pharmaceutically acceptable vehicle capable of acting as a depot. In the subject methods, the chemotherapeutic agent and membrane permeant are administered at least proximal to a target site of the host. Administration of chemotherapeutic agents in accordance with the subject methods results in improved efficacy of, and/or decreased host toxicity to, the intralesionally administered chemotherapeutic agent.
摘要翻译：提供了通过与细胞膜透过物一起施用化学治疗剂来治疗患有细胞增殖性疾病的宿主的方法。任选地，细胞膜渗透剂和/或化学治疗剂将存在于能够用作贮库的药学上可接受的载体中。在主题方法中，化学治疗剂和膜渗透剂至少在宿主的靶位点附近施用。根据本发明方法施用化学治疗剂导致对病灶内施用的化学治疗剂的改善的功效和/或降低的宿主毒性。

8. 发明授权

US07822651B2 Method for managing returns 有权
标题翻译：管理退货的方法
公开(公告)号：US07822651B2
公开(公告)日：2010-10-26
申请号：US10612659
申请日：2003-07-02
申请人： Delma S. Hume , Robert L. Flint , Steven L. Guse , Robert J. Rachowicz , Dennis M. Brown , Milo O. Twist , Theresa D. Wire
发明人： Delma S. Hume , Robert L. Flint , Steven L. Guse , Robert J. Rachowicz , Dennis M. Brown , Milo O. Twist , Theresa D. Wire
IPC分类号： G06F17/60
CPC分类号： G06Q10/0837 , G06Q10/06 , G06Q10/087 , G06Q30/0601
摘要： There are many situations where returns are needed to further business or other objectives. For example, in remanufacturing businesses, cores are rebuilt into remanufactured parts that are sold. To sustain remanufacturing, cores must be obtained. One way to assure a supply is to collect a deposit against a core return when a remanufactured part is sold. Tracking of cores and the associated liabilities for the deposits is complex. It is also beneficial to control the liabilities. Provided are systems, methods and steps that enable tracking and other effective management techniques to assure returns and liabilities are managed. In one embodiment, each core and an associated entitlement representative of a liability are tracked. Price changes can be made on core deposits without affecting the ability to control liabilities. The systems, processes and methods lend themselves to computer implementation and use in large businesses.
摘要翻译：在许多情况下，需要回报以进一步的业务或其他目标。例如，在再制造业务中，核心被重建到已经出售的再制造零件中。为了维持再制造，必须获得核心。确保供应的一种方法是在再制造零件出售时收取核心回报的存款。核心跟踪和相关负债的存款是复杂的。控制负债也是有益的。提供的系统，方法和步骤能够跟踪和其他有效的管理技术，以确保回报和负债得到管理。在一个实施例中，跟踪代表责任的每个核心和相关权利。核心存款可以进行价格变动，而不影响负债的控制能力。系统，流程和方法适用于大型企业的计算机实现和使用。

9. 发明授权

US07135481B2 Naphthalimide compositions and uses thereof 失效
标题翻译：邻苯二甲酰亚胺组合物及其用途
公开(公告)号：US07135481B2
公开(公告)日：2006-11-14
申请号：US11067074
申请日：2005-02-25
申请人： Dennis M. Brown
发明人： Dennis M. Brown
IPC分类号： A61K31/473
CPC分类号： A61K31/7048 , A61K31/4375 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/475 , A61K31/505 , A61K31/513 , A61K31/52 , A61K31/55 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Methods of treating a solid tumor are disclosed comprising administering amonafide in combination with an antiproliferative agent.
摘要翻译：公开了治疗实体瘤的方法，其包括与抗增生剂组合施用阿莫奈酯。

10. 发明授权

US5290552A Surgical adhesive material 失效
标题翻译：手术粘合剂材料
公开(公告)号：US5290552A
公开(公告)日：1994-03-01
申请号：US855921
申请日：1992-03-23
申请人： David H. Sierra , Edward E. Luck , Dennis M. Brown
发明人： David H. Sierra , Edward E. Luck , Dennis M. Brown
IPC分类号： A61L24/00 , A61L24/10 , A61K35/16 , A61K37/547
CPC分类号： A61L24/102 , A61L24/0005 , A61L24/0084 , Y10S514/801
摘要： The present invention provides a surgical adhesive comprising, in an aqueous composition, fibrinogen, FXIII, collagen, thrombin, Ca.sup.2+ and optionally, an antifibrinolytic agent. The present adhesive may be formed from the patient's plasma without the use of any added reagents for concentration or isolation of the fibrinogen. Conveniently, the adhesive is formulated as a two-part composition which is mixed together just prior to use.
摘要翻译：本发明提供一种手术粘合剂，其在水性组合物中包含纤维蛋白原，FXIII，胶原，凝血酶，Ca 2+和任选的抗纤维蛋白溶解剂。本发明的粘合剂可以由患者的血浆形成，而不使用用于浓缩或分离纤维蛋白原的任何添加的试剂。方便地，粘合剂被配制为在使用之前混合在一起的两部分组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式